The group of lifelong intestinal conditions known as inflammatory bowel disease (IBD), which includes Crohn's disease and ...
In patients with inflammatory bowel disease, severe gastrointestinal infections may trigger disease flares, requiring ...
Ultra-processed foods are everywhere – from snacks and frozen meals to sauces and cereals – and while they’re undeniably ...
IBD research, for all its sophistication, has been searching under the lamppost — sequencing, mapping and quantifying what can be seen. But the key may lie in the park, in the unseen intersections of ...
Objective To examine the associations between the number of days per week achieving various daily step thresholds and all-cause mortality and cardiovascular disease (CVD) incidence in older women.
UC San Diego researchers have resolved a decades-long debate about the role of the first Crohn’s disease gene linked to an increased risk of developing the autoimmune condition. The human digestive ...
1. Add 2 black pepper corns, 2 black pepper cloves and 1 tbsp fennel in a pot. 2. Add a pinch of sea salt if you like and top ...
Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its ...
Everyday Health on MSN
How to Protect Against Blood Clots if You Have Ulcerative Colitis
People with inflammatory bowel disease, like ulcerative colitis, are 2 to 3 times more likely to develop blood clots than those without IBD. Here’s how to protect yourself.
Oct 15 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and Omeros (OMER.O), opens new tab have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...
Novo Nordisk NOVO.B-0.54%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...
Novo Nordisk said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros for up to $2.1 billion. Under the asset purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results